Luxembourg · Delayed Price · Currency is EUR CTI BioPharma Statistics
Total Valuation
LUX:SACIL has a market cap or net worth of EUR 57.70 million. The enterprise value is 56.76 million.
| Market Cap | 57.70M |
| Enterprise Value | 56.76M |
Important Dates
The next estimated earnings date is Wednesday, September 24, 2025.
| Earnings Date | Sep 24, 2025 |
| Ex-Dividend Date | May 14, 2025 |
Share Statistics
| Current Share Class | 2.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.30 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -177.38 |
| EV / Sales | 0.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.43 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -0.37% |
| Revenue Per Employee | 290,990 |
| Profits Per Employee | -477 |
| Employee Count | 671 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LUX:SACIL has paid 4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -5.00% |
| 50-Day Moving Average | 26.74 |
| 200-Day Moving Average | 27.40 |
| Relative Strength Index (RSI) | 40.76 |
| Average Volume (20 Days) | 1 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LUX:SACIL had revenue of EUR 195.25 million and -320,000 in losses. Loss per share was -0.15.
| Revenue | 195.25M |
| Gross Profit | 70.62M |
| Operating Income | -328,000 |
| Pretax Income | -316,000 |
| Net Income | -320,000 |
| EBITDA | n/a |
| EBIT | -328,000 |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 1.71 million in cash and 772,000 in debt, giving a net cash position of 940,000.
| Cash & Cash Equivalents | 1.71M |
| Total Debt | 772,000 |
| Net Cash | 940,000 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 80.47M |
| Book Value Per Share | 37.10 |
| Working Capital | 20.86M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 36.17%, with operating and profit margins of -0.17% and -0.16%.
| Gross Margin | 36.17% |
| Operating Margin | -0.17% |
| Pretax Margin | -0.16% |
| Profit Margin | -0.16% |
| EBITDA Margin | n/a |
| EBIT Margin | -0.17% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.70, which amounts to a dividend yield of 2.63%.
| Dividend Per Share | 0.70 |
| Dividend Yield | 2.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 2.63% |
| Earnings Yield | -0.55% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LUX:SACIL has an Altman Z-Score of 2.22 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 1 |